A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR

Phase 1 Terminated 9 enrolled Dr David Ziegler Engeneic Pty Limited · collab

NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, sequential dose exploration study of single agent EEDVSMit administered by intravenous (IV) infusion twice weekly, followed by weekly maintenance dosing, in children with recurrent/refractory solid or CNS tumours.

Timeline

Start: 2016-02-08
Primary completion: 2021-12-29
Completion: 2021-12-29

Outcome

Outcome not reported

Stopped: “Study medication no longer in production”

Publications

Evans L, Walker R, MacDiarmid J, Brahmbhatt H, Anazodo A, McCowage G, Gifford AJ, Kavallaris M, Trahair T, Ziegler DS. A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor. Target Oncol. 2024 May;19(3):333-342. doi: 10.1007/s11523-024-01051-2. Epub 2024 Mar 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EEDVSMit	Other / unclassified	5e+08 unknown	Intravenous
Subject	EEDVSMit	Other / unclassified	5e+09 unknown	Intravenous
Subject	EEDVSMit	Other / unclassified	8e+09 unknown	Intravenous